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Abstract
Purpose—To develop an Arg-Gly-Asp (RGD) peptide-labeled chitosan nanoparticle (RGD-CH-
NP) as a novel tumor targeted delivery system for siRNA.
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Experimental Design—RGD peptide conjugated with CH by thiolation reaction was confirmed
by H-NMR. Binding of RGD-CH-NP with ανβ3 integrin was examined by flow cytometry and
fluorescence microscopy. Antitumor efficacy was examined in orthotopic mouse models of
ovarian carcinoma.
Results—We demonstrate that RGD-CH-NP loaded with siRNA significantly increased selective
intratumoral delivery in orthotopic animal models of ovarian cancer. In addition, we demonstrate
targeted silencing of multiple growth promoting genes (POSTN, FAK, and PLXDC1) along with
therapeutic efficacy in the SKOV3ip1, HeyA8, and A2780 models using siRNA incorporated into
RGD-CH-NP (siRNA/RGD-CH-NP). Furthermore, we demonstrate in vivo tumor vascular
targeting using the RGD-CH-NP by delivering PLXDC1-targeted siRNA into the ανβ3 integrin
positive tumor endothelial cells in the A2780 tumor-bearing mice. This approach resulted in
significant inhibition of tumor growth compared to controls.
Conclusions—This study demonstrates that RGD-CH-NP is a novel and highly selective
delivery system for siRNA with the potential for broad applications in human desease.
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Translational Relevance
We have developed a novel method for linking the RGD peptide to chitosan
nanoparticles (RGD-CH-NP) to increase selective delivery of siRNA. In addition, we
demonstrate targeted silencing of multiple growth promoting genes along with
therapeutic efficacy in orthotopic animal models of ovarian carcinoma. RGD-CH-NP is a
novel and highly selective delivery system for siRNA with the potential for broad
applications in human disease.
Introduction
RNA interference (RNAi)-based approaches hold great potential for cancer therapy (1-3).
SiRNA-based therapy may allow development of a broad armamentarium of targeted drugs
against genes that are difficult to target with other traditional approaches such as small
molecules or monoclonal antibodies. However, one of the key challenges to the use of
siRNA for therapy is the need for efficient intracellular delivery because unprotected siRNA
is rapidly cleared or degraded by nucleases. Delivery of siRNA across plasma membranes in
vivo has been achieved using delivery systems such as liposomes (4-6), nanoparticles(7-9)
and chemically modified siRNA (1). Although these delivery approaches have been shown
to be effective in pre-clinical models, many cannot be used in clinical settings due to non-
specific delivery, which may lead to unwanted or unexpected side effects. Therefore, to
overcome these limitations, novel delivery systems are needed. A desirable delivery system
should lead to enhanced concentrations of therapeutic payloads at disease sites, minimize
concerns about off-target effects (3), and ultimately raise the therapeutic index. Chitosan is
particularly attractive for clinical and biological applications due to its low immunogenicity,
low toxicity, and biocompatibility (10,11). In addition to its advantages such as protonated
amine groups, chitosan can increase binding efficiency with cells because of electrostatic
interactions (12).
For a targeted delivery system (3,8,13), various receptors on the tumor cell surface have
been established as a target binding site to achieve selective delivery. One such protein
receptor of interest is the ανβ3 integrin, which has been considered for selective delivery
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(14-17). The ανβ3 integrin is overexpressed in a wide range of tumors, and is largely absent
in normal tissues, which is a desirable feature for selective delivery. Here, we developed a
cyclic Arg-Gly-Asp (RGD) peptide-labeled chitosan nanoparticle (RGD-CH-NP) for tumor
targeted delivery of siRNA. The cyclic RGD has one or two ring structures, and provides
conformation stability and improved binding selectivity for the ανβ3 integrin. Moreover,
cyclic peptides are less susceptible to biodegradation than linear RGD peptides (18,19). In
the current study, we demonstrate highly selective delivery of targeted nanoparticles to ανβ3
integrin expressing cells and the therapeutic efficacy of this approach in multiple ovarian
cancer models.
Materials and Methods
Conjugation of RGD and CH
Conjugation of RGD (c[RGDfK (Ac-SCH2CO)], MW 719.82 Da) and CH (MW 50-190
KDa) is shown in Fig. 1A. The RGD and CH were conjugated by thiolation reaction using
cross-linking reagent, N-succinimidyl 3-(2-pyridyldithio)-propionate (SPDP). Briefly, 10.5
ml of 2 mg/ml CH solution (1% acetate buffer) was added to 700 μg of SPDP to react NH2
group of the CH for 4 hr at room temperature. After that, 500 μg of RGD was added to
SPDP-activated CH solution for 24 hr at room temperature. After this reaction, dialysis was
performed for 48 hr to isolate conjugates. The conjugates were confirmed by H-NMR (CH
and CH-RGD: 1% acetic acid included D2O, RGD: DMSOd6, 500 MHz, HRMAS-FT-
NMR, Bruker, Germany). In addition, to determine the RGD concentration in RGD-CH-
NPs, RGD peptide was labeled with FITC as shown in Supplementary Fig. S1 (20).
Preparation of siRNA/RGD-CH-NP
RGD-CH-NP was prepared based on ionic gelation of anionic TPP and siRNA. Briefly,
predetermined TPP (0.25% w/v) and siRNA (1 μg/μL) were added in RGD-CH solution,
and the siRNA/RGD-CH-NP were spontaneously formed under constant stirring at room
temperature. After incubation at 4 °C for 40 min, siRNA/RGD-CH-NP was collected by
centrifugation (Thermo Biofuge, Germany) at 13,000 rpm for 40 min at 4 °C. The pellet was
washed by sterile water 3 times to isolate siRNA/RGD-CH-NP, which was stored at 4 °C
until used.
Characteristics of siRNA/RGD-CH-NP
The RGD concentration in the RGD-CH-NPs was calculated by measuring FITC intensity
based on a calibration curve of standard concentration of FITC-labeled with RGD by a
fluorescence spectrophotometer (20). Size and zeta potential of RGD-CH-NP were
measured by light scattering with a particle size analyzer and Zeta Plus (Brookhaven
Instrument Co., CA), respectively. Co-incorporation of FITC-labeled RGD and Alexa555
siRNA into siRNA/RGD-CH-NP was observed by fluorescence microscopy, and the
physical morphology of siRNA/RGD-CH-NP was observed by SEM.
Cell lines and siRNA
The derivation and source of the human epithelial ovarian cancer cell lines SKOV3ip1,
HeyA8, A2780, A2780ip2, and murine ovarian endothelial cells (MOEC) have been
previously described (4,5,21). The POSTN siRNA (target sequence: 5′-
GGAUCUUGUGGCCCAAUUA-3′), FAK siRNA (target sequence: 5′-
CCACCUGGGCCAGUAUUAU-3′), PLXDC1 siRNA (target sequence:
5′GACACCUGCGUCCUCGA-3′), and control siRNA (target sequence: 5′-
UUCUCCGAACGUGUCACGU-3′) were purchased from Sigma (USA)(22).
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Binding of RGD-CH-NPs
To confirm the in vitro binding efficiency of RGD-CH-NP against ανβ3 integrin on the cell
surface, we conducted both flow cytometry analysis and fluorescence microscopy. To
measure binding efficiency of Alexa555 siRNA/RGD-CH-NP, cells were incubated for 20
min at 4 °C after NPs were added, and then cells were collected by centrifugation (1,500
rpm, 3 min). The binding efficiency was measured by flow cytometry (23,24). To observe
cell binding of RGD-CH-NP, cells were fixed in a chamber slide using 4%
paraformaldehyde and then the cells were stained with Hoechst 33258 for 10 min at 4 °C (to
stain nuclei blue) and observed under fluorescence microscopy (magnification ×200)
(23,24). In addition, we confirmed intracellular delivery of CH-NP or RGD-CH-NP by
confocal microscopy. Briefly, we added CH-NP or RGD-CH-NP in cells and then incubated
for 20 min at room temperature. After that, cells were fixed using 4% paraformaldehyde and
then the cells were stained with sytox green (to stain nuclei green) for 10 min at room
temperature and observed under confocal microscopy. To confirm binding of RGD-CH-NP
by tumor cells, morphology of the cells was observed by TEM (23,24).
In vivo delivery of siRNA/RGD-CH-NP
Detection of uptake of Alexa555 siRNA/RGD-CH-NP was performed as described
previously (25,26). Relevant tissues were harvested after single injection of either control
siRNA/CH-NP, Alexa555 siRNA/CH-NP or Alexa555 siRNA/RGD-CH-NP into
SKOV3ip1-bearing mice. Uptake efficiency was determined by the percentage of Alexa555
siRNA-labeled NPs location into tissue in 5 random fields at ×200 magnification for each
tumor and organ. In addition, to confirm ανβ3 integrin-mediated delivery of RGD-CH-NP,
we performed ανβ3 integrin staining in tumor tissues as described above.
Western blot analysis
The preparation of cultured cell lysates and tumor tissue lysates has been previously
described (5,27). Protein concentrations were determined using a BCA Protein Assay
Reagent Kit (Pierce Biotech., Rockford, IL) and aliquots of 20 μg protein were subjected to
gel electrophoresis on 7.5% or 10% SDS-PAGE gels. Transfer to membranes and
immunoblotting was performed as described previously (28).
Orthotopic in vivo model of ovarian cancer and tissue processing
Female athymic nude mice (NCr-nu) were purchased from the National Cancer Institute-
Frederick Cancer Research and Development Center (Frederick, MD) and maintained as
previously described (29). All mouse studies were approved by the M. D. Anderson Cancer
Center Institutional Animal Care and Use Committee. The mice used for in vivo experiments
were 8 to 12 weeks old. To produce tumors, SKOV3ip1, HeyA8, and A2780 (1 × 106 cells
per 0.2 ml HBSS) cells were injected into the peritoneal cavity (i.p.) of mice. Mice (n= 10
per group) were monitored daily for adverse effects of therapy and were sacrificed when any
of the mice seemed moribund.
To assess tumor growth, treatment began 1 week after i.p. injection of tumor cells into mice.
Each siRNA-incorporated CH-NP or RGD-CH-NP was given twice weekly at a dose of 150
μg/kg body weight through i.v injection. Docetaxel was diluted in PBS and injected i.p once
a week, at a dose of 100 μg in 200 μl. Treatment continued until mice became moribund
(typically 4 to 5 weeks depending on tumor-cell). Mouse weight, tumor weight, number of
nodules, and distribution of tumors in mice were recorded at the time of sacrifice. The
individuals who performed the necropsies, tumor collections, and tissue processing were
blinded to the treatment group assignments. Tissue specimens were fixed either with
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formalin or OCT (optimum cutting temperature; Miles, Inc., Elkhart, IN) or were snap
frozen.
Real time quantitative RT-PCR
Relative expression of POSTN and FAK mRNA in mice after treatment was determined by
real-time quantitative RT-PCR using 50 ng total RNA isolated from treated tumor tissue
using the RNeasy Mini Kit (Qiagen). Relative expression values were obtained using the
2-ΔΔCT method, and normalized to control for percent fold changes (30).
Immunohistochemical staining
Immunohistochemical (IHC) analysis was performed on tumor tissue from mice that were
treated by i.v. injection of siRNA/CH-NP or siRNA/RGD-CH-NP. Procedures for IHC
analysis of cell proliferation (Ki67), microvessel density (CD31), and POSTN expression
(POSTN antibody) were performed as described previously (27,31). All of these analyses
were recorded in 5 random fields for each slide at ×100 magnification. In addition, terminal
deoxynucleotidyl transferase-mediated nick end labeling (TUNEL) was performed as
described previously to determine cell apoptosis (32). The quantification of apoptotic cells
was calculated by the number of apoptotic cells in 5 random fields at ×200 magnification.
All staining was quantified by 2 investigators in a blinded fashion.
Statistical analysis
Differences in continuous variables were analyzed using the student's t test for comparing
two groups and ANOVA was performed to compare differences for multiple group
comparisons. For values that were not normally distributed, the Mann-Whitney rank sum
test was used. The statistical package for the Social Sciences (SPSS, Inc.) was used for all
statistical analyses. A p value of <0.05 was considered statistically significant.
Results
Characteristics of siRNA incorporated RGD-CH-NPs (siRNA/RGD-CH-NP)
In this study, we selected the ανβ3 integrin as a target receptor since it is selectively
expressed in a large proportion of ovarian cancer cells and associated tumor vasculature.
Therefore, we utilized a well-characterized targeting peptide, Arg-Gly-Asp (RGD), which
can bind specifically to the ανβ3 integrin (33,34). We first conjugated the RGD peptide with
CH by thiolation reaction of SPDP (Fig. 1A) and the conjugates were confirmed by H-NMR
analysis (Supplementary Fig. S2). As shown in Supplementary Fig. S2C, the peaks for the
CH of benzene group in RGD (1) and CH2 of methylene in RGD (1.5 ppm) (2) were
observed at 7-8 ppm and 1-2 ppm, respectively. Additionally, conjugation of RGD with CH
and CH-NP was measured using FITC-labeled RGD by fluorescence intensity
(Supplementary Fig. S1). Conjugation yield of RGD with CH is up to 60% (data not shown)
and RGD concentration on RGD-CH-NP was determined by measuring FITC intensity
based on a calibration curve of standard concentration of FITC-labeled with RGD.
Based on conjugation of RGD-CH, RGD-CH-NPs were prepared. We prepared 5 different
siRNA/RGD-CH-NPs with varying amounts of RGD (Fig. 1B). The size and zeta potential
of siRNA/RGD-CH-NPs were around 200 nm and 40 mV, respectively (Fig. 1B). The
histogram of RGD-CH-NP 5 is shown in Supplementary Fig. S3. These experiments
indicate that RGD conjugation with CH-NP does not affect formation and physicochemical
properties of siRNA/RGD-CH-NPs. Additionally, the incorporation of RGD and siRNA into
RGD-CH-NP 5 was confirmed by fluorescence microscopy using FITC-labeled RGD
(green) and Alexa555-labeled siRNA (red) (Fig. 1C, upper panel). The morphology of
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siRNA/RGD-CH-NP 5 was determined by scanning electron microscopy (SEM). The
particles were spherical in shape and the size was around 200 nm (Fig. 1C, lower panel).
RGD-CH-NP enhances binding efficiency on ανβ3 integrin expressing tumor cells
We first assessed the expression of ανβ3 integrin in ovarian cancer cell lines by flow
cytometry. While A2780ip2 cells were negative, the SKOV3ip1 cells showed positive
expression on the cell membrane against the ανβ3 integrin (Fig. 2A). We next studied the
binding efficiency of siRNA/RGD-CH-NPs in both cell lines with different concentrations
of RGD (Fig. 1B). As expected, little binding was observed in A2780ip2 cells at any of the 5
different formulations tested (Fig. 2B). However, in the ανβ3 positive SKOV3ip1 cells,
binding increased in a RGD concentration dependent manner. Among the five formulations,
the siRNA/RGD-CH-NP 5 (1.45 μg RGD/mg chitosan) showed the highest binding (Fig.
2B). Therefore, we selected siRNA/RGD-CH-NP 5 for subsequent experiments. We next
confirmed binding efficiency of Alexa555-labeled (Alexa555) siRNA/RGD-CH-NP by
fluorescence microscopy against tumor cells. Alexa555 siRNA/RGD-CH-NP showed higher
binding efficiency (94.25% induction vs CH-NP) in the SKOV3ip1 cells compared to non-
RGD labeled CH-NP. In contrast, similar binding efficiency was observed in the A2780ip2
cells between RGD-CH-NP and CH-NP (Fig. 2C). To observe binding of the RGD-CH-NP
in tumor cells, we utilized TEM. In the SKOV3ip1 cells, the RGD-CH-NP showed higher
binding compared to the ανβ3-negative A2780ip2 cells (Fig. 2D). In addition, we observed
intracellular delivery of CH-NP or RGD-CH-NP using confocal microscopy. Alexa555
siRNA/RGD-CH-NP resulted in higher intracellular efficiency in the SKOV3ip1 cells
compared to non-RGD labeled CH-NP (Supplementary Fig. S4).
RGD-CH-NP enhances targeted delivery to tumor tissues
Prior to performing proof-of-concept in vivo efficacy studies, we tested the extent of in vivo
delivery following a single intravenous injection of Alexa555 siRNA/RGD-CH-NP into
SKOV3ip1-bearing mice after 48 hr. The siRNA was observed in >80% of fields examined,
and demonstrated up to 3-fold higher localization into tumor tissues compared to CH-NP
(Fig. 3A). Additionally, we also stained harvested tumors for the ανβ3 integrin to evaluate
co-localization. The Alexa555 siRNA/RGD-CH-NP (red) consistently showed co-
localization (yellow) with the ανβ3 integrin (green) in tumor tissues (Fig. 3B). In contrast,
delivery with siRNA/CH-NP demonstrated Alexa555 positive siRNA in both ανβ3 positive
and negative cells. These findings indicate that siRNA/RGD-CH-NPs indeed result in
selective delivery into ανβ3 positive cells. We also examined other organs including liver,
kidney, spleen, lung, heart and brain for delivery of siRNA using either the CH-NP or RGD-
CH-NP. However, minimal siRNA RGD-CH-NP was observed in these organs as compared
to CH-NP due to the greater binding specificity for RGD-CH-NP in tumor tissues (Fig. 3C).
Therapeutic efficacy of gene silencing with targeted RGD-CH-NP
To determine the effectiveness of gene silencing and potential therapeutic efficacy, we
focused on targeting periostin (POSTN), which plays a significant role in cell invasion,
survival, and angiogenesis, leading to increased metastasis of cancer cells (35). The
SKOV3ip1 and A2780 models were selected for these experiments as they have increased
POSTN levels (Supplementary Fig. S5). Following a single intravenous injection of POSTN
siRNA/RGD-CH-NP (150 μg siRNA/kg body weight) into SKOV3ip1-bearing mice, tumors
were harvested. POSTN expression was reduced by >51% in RGD-CH-NP treated tumors
compared to control siRNA/CH-NP and by >20% compared to CH-NP at 24 hr (Fig. 4A).
On the basis of this result, we evaluated POSTN expression by immunohistochemstry (IHC)
analysis. Delivery of POSTN siRNA with RGD-CH-NP resulted in significantly greater
inhibition of POSTN expression in tumor tissues as compared to POSTN siRNA/CH-NP or
control siRNA/CH-NP at 24 hr (Fig. 4B).
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We next examined the therapeutic efficacy of POSTN silencing with POSTN siRNA/RGD-
CH-NP in mice bearing orthotopic SKOV3ip1 (ανβ3 positive) or A2780 (ανβ3 negative)
tumors. Seven days following injection of tumor cells into the peritoneal cavity, mice were
randomly allocated to the following groups (n=10 mice/group): 1) control siRNA/CH-NP +
PBS, 2) POSTN siRNA/CH-NP + PBS, 3) POSTN siRNA/RGD-CH-NP + PBS, 4) control
siRNA/CH-NP + docetaxel, 5) POSTN siRNA/CH-NP + docetaxel and 6) POSTN siRNA/
RGD-CH-NP + docetaxel. All mice were sacrificed when animals in any group appeared
moribund (4 to 5 weeks after cell injection depending on the cell line). In the SKOV3ip1
model, POSTN siRNA/RGD-CH-NP + PBS resulted in significant inhibition of tumor
growth compared to POSTN siRNA/CH-NP + PBS (24% reduction; p <0.04) and control
siRNA/CH-NP + PBS (71% reduction, p <0.001). Notably, combination of POSTN siRNA/
RGD-CH-NP + docetaxel showed the greatest inhibition of tumor growth compared to
control siRNA/CH-NP + docetaxel (32% reduction, p <0.006) and CH-NP + docetaxel (22%
reduction, p <0.01; Fig. 5A). After treatment, the decrease in POSTN mRNA level was
confirmed by qRT-PCR (Fig. 5A). In the A2780 model, POSTN siRNA/RGD-CH-NP +
PBS showed significant inhibition of tumor growth compared to control siRNA/CH-NP +
PBS (73% reduction, p <0.01), however, POSTN siRNA/RGD-CH-NP + PBS showed no
additional benefit compared to POSTN siRNA/CH-NP + PBS (p <0.22; Fig. 5B). As above,
decrease in POSTN mRNA level was confirmed by qRT-PCR (Fig. 5B). There were no
differences in total body weight, feeding habits or behavior between the groups, suggesting
that there were no overt toxicities related to therapy.
To determine potential mechanisms underlying the efficacy of siRNA/RGD-CH-NP therapy
in tumor tissues, we examined tumors for markers of cell proliferation (Ki67), microvessel
density (MVD, CD31), and apoptosis (TUNEL). In the SKOV3ip1 model, POSTN siRNA/
RGD-CH-NP + PBS showed significant inhibition of cell proliferation (p <0.001 vs control
siRNA/CH-NP + PBS; p <0.05 vs POSTN siRNA/CH-NP + PBS), MVD (p < 0.001 vs
control siRNA/CH-NP + PBS; p <0.01 vs POSTN siRNA/CH-NP + PBS), and increased
apoptosis (p < 0.001 vs control siRNA/CH-NP + PBS; p <0.002 vs POSTN siRNA/CH-NP
+ PBS). The combination group of POSTN siRNA/RGD-CH-NP + docetaxel had
significantly reduced cell proliferation (p <0.05) and MVD (p <0.001), and increased
apoptosis as compared to the single treatment groups (p <0.001, Fig. 5C). In the A2780
model, POSTN siRNA/RGD-CH-NP + docetaxel showed significant inhibition of cell
proliferation (p <0.003), MVD (p <0.001), and increased cell apoptosis compared to control
siRNA/CH-NP + PBS (p <0.004). As expected, neither POSTN siRNA/RGD-CH-NP nor
POSTN siRNA/CH-NP showed any significant effects on cell proliferation (p <0.10) and
apoptosis (p <0.33, Supplementary Fig. S6A).
To establish that the effects of RGD-CH-NP are not unique to just one target, we also
performed in vivo experiments with siRNA against additional targets. We targeted FAK due
to its prominent role in ovarian cancer growth and progression (36). The HeyA8 cells are
both ανβ3 integrin and FAK positive (37). Mice were randomly allocated to one of
following 6 groups (n=10 mice/group): 1) control siRNA/CH-NP + PBS, 2) FAK siRNA/
CH-NP + PBS, 3) FAK siRNA/RGD-CH-NP + PBS, 4) control siRNA/CH-NP + docetaxel,
5) FAK siRNA/CH-NP + docetaxel and 6) FAK siRNA/RGD-CH-NP + docetaxel.
Treatment with FAK siRNA/RGD-CH-NP + PBS resulted in significant inhibition of tumor
growth as compared to FAK siRNA/CH-NP + PBS (p <0.04) and control siRNA/CH-NP +
PBS (p <0.001, Fig. 5D). Combination of FAK siRNA/RGD-CH-NP + docetaxel resulted in
the greatest effect on tumor growth compared to the other single treatment groups (p <0.02)
and FAK siRNA/CH-NP + PBS (p <0.01, Fig. 5D). After treatment, FAK mRNA levels (by
qRT-PCR) were found to be significantly lower in the FAK siRNA treated groups (Fig. 5D).
Treatment with FAK siRNA/RGD-CH-NP + docetaxel resulted in significant inhibition of
cell proliferation (p <0.05), MVD (p <0.01), and increased cell apoptosis (p <0.01). The
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combination group of FAK siRNA/RGD-CH-NP + docetaxel showed even further decreases
in cell proliferation (p <0.001) and MVD (p <0.03), and increased apoptosis compared to the
single treatment group (p < 0.04, Supplementary Fig. S6B).
RGD-CH-NP targets tumor vasculature
Since the ανβ3 integrin is known to be selectively expressed in the tumor vasculature, we
also selected PLXDC1, a target we recently identified as being upregulated in ovarian
cancer vasculature (38). We first confirmed that the mouse ovarian endothelial cells (in
vitro) and mouse origin tumor vasculature in A2780 tumor tissue (in vivo) express the ανβ3
integrin even though the A2780 cells were negative for ανβ3 integrin expression
(Supplementary Fig. S7A and B). As expected, the A2780 tumors harvested from mice
lacked ανβ3 expression on tumor cells; however, it was clearly present in tumor vasculature
compared to the corpus luteum in the mouse ovary (Supplementary Fig. S7B). Prior to in
vivo experiments, we confirmed delivery of Alexa555 siRNA/RGD-CH-NP into the tumor
vasculature after injection into A2780-bearing mice. Alexa555 siRNA/RGD-CH-NP showed
co-localization (yellow) with endothelial cells (CD31, green) in the tumor vasculature
compared to CH-NP (Supplementary Fig. S7C). We next carried out experiments with
siRNA targeting PLXDC1 (38), which was incorporated into RGD-CH-NP. For these
experiments, A2780 tumor bearing mice were randomly allocated to one of the following 3
groups (n=10 mice/group): 1) control siRNA/CH-NP, 2) PLXDC1 siRNA/CH-NP, and 3)
PLXDC1 siRNA/RGD-CH-NP. Treatment with PLXDC1 siRNA/RGD-CH-NP resulted in
significant inhibition of tumor growth compared to control siRNA/CH-NP (87% reduction;
p <0.001, Fig. 6A). The targeted delivery of PLXDC1 siRNA with RGD-CH-NP resulted in
even greater efficacy compared to PLXDC1 siRNA with CH-NP (p <0.01, Fig. 6A). Since
the A2780 cells lack ανβ3 integrin expression, these results suggest that the RGD-mediated
CH-NP targeting is highly effective in targeting the tumor vasculature. We next examined
the effects of PLXDC1 gene silencing on the tumor vasculature. PLXDC1 siRNA/RGD-CH-
NP resulted in increased apoptosis in the tumor vasculature compared to PLXDC1 siRNA/
CH-NP (Fig. 6B). Additionally, to confirm PLXDC1 silencing in the tumor vasculature
following PLXDC1 siRNA/RGD-CH-NP injection into A2780-bearing mice, we performed
dual immunofluorescence (IF) staining for endothelial cells (CD31, red) and PLXDC1
(green). The PLXDC1 siRNA/RGD-CH-NP treated group resulted in complete PLXDC1
silencing in the tumor vasculature compared to PLXDC1 siRNA/CH-NP (Fig. 6C).
Discussion
We demonstrate here that a novel receptor-targeted delivery system (RGD-CH-NP) loaded
with siRNA targeted to key ovarian cancer associated genes leads to potent anti-tumor
efficacy in ovarian carcinoma. This approach has broad utility for selectively targeting
tumor cells as well as the associated endothelial cells. The RGD-CH-NP was effective in
silencing multiple targets of interest and in achieving therapeutic efficacy.
RNAi-based cancer therapy is a highly specific method of gene silencing, but hurdles related
to systemic in vivo delivery of siRNA need to be overcome to realize its full potential in
clinical settings. Moreover, delivery efficiency of free siRNA without the use of a
nanoparticle is quite low and most of the free siRNA is rapidly degraded following
intravenous injection (5,39). Therefore, to overcome this limitation, selective targeted
delivery systems are needed. While a number of nanoparticle systems have been utilized for
therapeutic applications, most of these are widely distributed in the body, and could lead to
undesirable toxicities in normal tissues. In addition, wide drug distribution may require
higher doses for gene silencing in the target tissue of interest. Therefore, to overcome these
limitations against conventional passive delivery, targeted delivery is highly desirable.
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Targeted delivery systems have been designed to increase or facilitate uptake into target
tissue (3), and to protect siRNA payloads and inhibit nonspecific delivery (3). Recent work
comparing non-targeted and targeted nanoparticles has shown that the primary role of the
targeting ligands is to enhance selective cellular uptake into cancer cells and to minimize
accumulation in normal tissues (40). The addition of targeting ligands that provide specific
nanoparticle-cell surface interactions can play a vital role in the ultimate location of
nanoparticles. For example, nanoparticles can be targeted to cancer cells if their surfaces
contain moieties such as peptides, proteins or antibodies. These moieties can bind with
cancer cell-surface receptor proteins such as transferring (41) or folate (42) receptors, which
are known to be increased in number on a wide range of cancer cells. These targeting
ligands enable nanoparticles to bind to cell-surface receptors and penetrate cells by receptor-
mediated endocytosis. However, a limited number of nanoparticle systems have reached
clinical development (40).
Nanoparticles can carry a large payload of drugs as compared to antibody conjugates
(40,43). Furthermore, nanoparticle payloads are frequently located within the particles, and
their type and number may not affect the pharmacokinetics and biodistribution of the
nanoparticles. This is unlike molecular conjugates in which the type and number of
therapeutic entities conjugated to the targeting ligand significantly modifies the overall
properties of the conjugate.
Several synthetic materials have been proposed for effective non-viral siRNA delivery
systems such as lipid-based particles, oligofectamine, cyclodextrin, polyethyleneimine, and
cholesterol (3). Although many types of compounds have potential utility as delivery agents,
some have concerns regarding safety. For example, toxicity of cationic lipid particles has
been reported both in vitro and in vivo (44,45), and some synthetic agents have been found
to induce a gene signature of their own that might increase the off-target effects of siRNA
(46,47). Therefore, development of siRNA therapeutics for cancer treatment requires
clinically suitable, safe and effective drug delivery systems.
Chitosan nanoparticles (CH-NP) have been recently developed for siRNA delivery
(12,48,49). Chitosan is an attractive nanoparticle for siRNA delivery because its positive
charge allows transport across cellular membranes and subsequent endocytosis. Moreover,
chitosan is biodegradable, biocompatible, and has low immunogenicity (10,12,48). Chitosan
nanoparticles without a therapeutic payload have no effect on tumor growth compared to
untreated animals (50). The ανβ3 integrin is known to be overexpressed in most cancer cells
and the tumor vasculature (33,37,51). The ανβ3 integrin is a family of cell surface receptors,
which plays an important role in tumor biology and may serve as a useful target (13). In
addition to its role in cell matrix recognition, the ανβ3 integrin has been a focus for drug
delivery strategies since it assists with internalization and gene transfer (33). In the current
study, we developed and characterized RGD-CH-NP incorporated with siRNA as an ανβ3
integrin-targeted delivery system because of its high affinity and highly specific binding.
Indeed, our targeted delivery-mediated gene silencing significantly enhanced anti-tumor
therapeutic efficacy compared to a non-targeted delivery system in preclinical ovarian
cancer models. While the RGD ligand can be useful for binding to integrin family members,
additional targeting approaches may be useful. Nevertheless, the targeted delivery strategy
presented here has broad potential as a delivery platform in human disease and could be
adapted for other targeting ligands.
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Refer to Web version on PubMed Central for supplementary material.
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Fig. 1.
A, Conjugation of RGD to chitosan (CH). Physical properties of siRNA/RGD-CH-NPs. B
(upper panel), RGD concentration in the siRNA/RGD-CH-NPs was calculated by measuring
FITC intensity based on a calibration curve of standard concentration of FITC-labeled with
RGD by fluorescence spectrophotometry. B (middle and lower panel), Size and zeta
potential of siRNA/RGD-CH-NPs were measured by light scattering with a particle size
analyzer and Zeta Plus, respectively. C, Incorporation of FITC-labeled RGD (green) and
Alexa555 siRNA (red) into siRNA/RGD-CH-NPs was observed by fluorescence microscopy
(magnification ×400, upper panel, scale bar: 1 μm). Morphology of siRNA/RGD-CH-NP 5
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was examined by scanning electron microscopy (SEM, lower panel). Error bars represent
s.e.m. *p<0.05.
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Fig. 2.
Binding of siRNA/RGD-CH-NPs against ovarian cancer cells in vitro. A, ανβ3 integrin
expression on SKOV3ip1 or A2780ip2 cells by flow cytometry. Cells were incubated in
RPMI-1640 supplemented with 10% fetal bovine serum at 37 °C for 24 hr, and then washed
and incubated with 2.5 μg of either Alexa555 labeled siRNA/CH-NPs or siRNA/RGD-CH-
NPs in PBS for 20 min at 4 °C. B, Binding of siRNA/RGD-CH-NPs with different
concentrations of RGD peptide by flow cytometry. C, Binding of Alexa555 siRNA/RGD-
CH-NPs and Alexa555 siRNA/CH-NP in SKOV3ip1 or A2780ip2 cells. Cells were fixed in
a chamber slide using 4% paraformaldehyde and then nuclei (blue) were stained with
Hoechst 33258 for 10 min, and binding was analyzed by fluorescence microscopy
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(magnification ×200). Quantitative differences were analyzed by fluorescence intensity of
Alexa555 (red)/Hoechst 33358 (blue). Error bars represent s.e.m. *p <0.01. D, Binding of
RGD-CH-NPs in SKOV3ip1 or A2780ip2 cells by TEM (N: nucleus, arrows: NPs, bar: 2
μm).
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Fig. 3.
In vivo delivery of Alexa555 siRNA/RGD-CH-NP. Tumor and organ tissues were harvested
after single injection of either control siRNA/CH-NP, Alexa555 siRNA/CH-NP, or
Alexa555 siRNA/RGD-CH-NP into SKOV3ip1-bearing mice. Uptake efficiency was
determined by the percentage of Alexa555 siRNA-labeled NPs in 5 random fields (original
magnification ×200): A, Tumor and C, Various organs. B, Co-localization of Alexa 555
siRNA/RGD-CH-NP or CH-NP (red) and ανβ3 integrin (green) in tumor tissues (original
magnification ×200). All of these analyses were recorded in 5 random fields for each slide.
Error bars represent s.e.m. *p <0.05.
Han et al. Page 17
Clin Cancer Res. Author manuscript; available in PMC 2011 August 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Fig. 4.
Effect of POSTN down regulation following intravenous injection of POSTN siRNA/RGD-
CH-NP into SKOV3ip1-bearing mice. A, Western blot analysis was done for POSTN
expression in tumor tissue (20 μg of protein used). Quantitative differences were determined
by densitometry analysis. B, POSTN expression in tumor tissues was assessed by
immunohistochemistry at 24 hr. All of these analyses were recorded in 5 random fields for
each slide and quantitative difference was determined by positive/negative expression of
cells for staining (magnification ×100). Error bars represent s.e.m. *p <0.05.
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Fig. 5.
Effect of siRNA/RGD-CH-NP on ovarian cancer growth. Treatment was started 1 week
after intraperitoneal injection of tumor cells into mice: A, SKOV3ip1 and B, A2780. Either
siRNA-incorporated into CH-NP or RGD-CH-NP was given twice weekly at a dose of 150
μg/kg body weight through intravenous injection. Docetaxel was diluted in PBS and injected
intraperitoneally once per week, at a dose of 100 μg, in 200 μl of PBS. Treatment was
continued until mice in any group became moribund (typically 4 to 5 weeks depending on
tumor cell). The fold change in levels of POSTN mRNA represents the mean of triplicate
experiments by qRT-PCR. C, Immunohistochemistry for cell proliferation (Ki67,
magnification ×100), microvessel density (CD31, magnification ×100), and TUNEL (bar: 50
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μm) was performed on SKOV3ip1-tumor tissues following treatment with POSTN siRNA/
RGD-CH-NP or CH-NP. All of these analyses were recorded in 5 random fields for each
slide. D, HeyA8 tumor model treated with FAK siRNA/RGD-CH-NP or CN-NP. The fold
change in FAK mRNA levels represents the mean of triplicate experiments by qRT-PCR.
Error bars represent s.e.m. *p <0.05.
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Fig. 6.
Therapeutic efficacy of siRNA/RGD-CH-NP against A2780-bearing mice. A, Anti-tumor
effect of mouse PLXDC1 siRNA/RGD-CH-NP or CH-NP in the A2780 tumor model. Error
bars represent s.e.m. *p <0.05. B, Effect of PLXDC1 siRNA/RGD-CH-NP treatment on
apoptosis in the tumor vasculature. Tumor sections were stained with CD31 (red) and
TUNEL (green) using double immunofluorescence staining. Colocalization of endothelial
cells undergoing apoptosis appears yellow (magnification ×400). All of these analyses were
recorded in 5 random fields for each slide and quantitative differences were analyzed by
positive expression of TUNEL/CD31. C, Tumor sections were stained with CD31 (red) and
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PLXDC1 (green) using immunofluorescence staining to examine PLXDC1 silencing in the
tumor vasculature (magnification ×400).
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